SynthesisAdvances in therapy2026
Efficacy and Safety of Endoscopic Treatment for Chronic Hemorrhagic Radiation Enteropathy: A Systematic Review and Meta-analysis.
Synthesis in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionChronic hemorrhagic radiation enteropathy, a common complication secondary to pelvic radiotherapy, can be treated by endoscopy. However, the efficacy and safety of endoscopic treatment have not been systematically assessed.
methodsPubMed, EMBASE, and Cochrane Library databases were searched to identify all relevant studies on endoscopic treatment for chronic hemorrhagic radiation enteropathy. A random-effects model was employed to perform meta-analyses. Pooled rates and weighted mean difference were calculated. Heterogeneity was explored through meta-regression, leave-one-out sensitivity, and subgroup analyses.
resultsOverall, 81 studies including 2626 patients with chronic hemorrhagic radiation enteropathy were eligible. Among them, argon plasma coagulation (APC) was performed in 2255 patients, with the rates of clinical success, endoscopic success, transfusion-free, recurrence, mild and moderate adverse events, and serious adverse events being 95%, 97%, 100%, 7%, 7%, and 0%, respectively; and the mean hemoglobin level increased by 20.61 g/L. Radiofrequency ablation was performed in 132 patients, with the rates of clinical success, endoscopic success, transfusion-free, recurrence, mild and moderate adverse events, and serious adverse events being 100%, 100%, 84%, 8%, 8% and 0%, respectively; and the mean hemoglobin level increased by 20.33 g/L. After laser treatment, cryotherapy, heater probe treatment, and bipolar electrocoagulation, the clinical success rates were 87%, 92%, 100%, and 94%, respectively; and the endoscopic success rates were 91%, 89%, 100%, and 100%, respectively.
conclusionEndoscopic treatments are often effective and safe for chronic hemorrhagic radiation enteropathy. APC is the most widely studied choice of endoscopic treatment. In future, head-to-head comparative studies are needed to explore their benefits and risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.